Xenon Pharmaceuticals Inc.
- Stock
- Ticker XENE
- ISIN CA98420N1050
- Nasdaq
- US listing in dollars
Performance, volatility and drawdowns of Xenon Pharmaceuticals Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $45,728. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −77.7% in 11/2017, measured from the peak in 03/2017. It took 15 months to get back to the old peak.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0.0 | 7.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income | -77 | -73 | -94 | -96 | -110 | -112 | -123 | -120 |
| EBITDA | -77 | -72 | -94 | -96 | -109 | -112 | -123 | -120 |
| Net income | -66 | -65 | -85 | -91 | -105 | -102 | -111 | -110 |
| Earnings per share | -0.84 | -0.83 | -1.07 | -1.15 | -1.31 | -1.17 | -1.11 | -1.11 |
| Balance sheet | ||||||||
| Total assets | 798 | 743 | 674 | 608 | 633 | 1,387 | 1,296 | 1,200 |
| Liabilities | 43 | 39 | 40 | 48 | 51 | 49 | 53 | 53 |
| Equity | 755 | 704 | 634 | 560 | 582 | 1,338 | 1,242 | 1,146 |
| Cash | 143 | 117 | 135 | 105 | 199 | 546 | 120 | 83 |
| Cash flow | ||||||||
| Operating cash flow | -54 | -62 | -64 | -72 | -81 | -89 | -95 | -90 |
| Capital expenditure | -0.8 | 0.0 | -0.2 | -0.3 | -0.3 | -0.1 | -0.3 | -0.3 |
| Free cash flow | -55 | -62 | -64 | -72 | -82 | -89 | -96 | -91 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2018 at +123.4%, weakest 2017 at −63.3%. 7 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 9 Nov 2026 | −$1.11 |
| 6 Aug 2026 | −$1.11 |
| 7 May 2026 | −$1.17 |
| 26 Feb 2026 | −$1.31 |
| 3 Nov 2025 | −$1.15 |
| 11 Aug 2025 | −$1.07 |
| 12 May 2025 | −$0.83 |
| 27 Feb 2025 | −$0.84 |
| 12 Nov 2024 | −$0.81 |
| 8 Aug 2024 | −$0.75 |
| 9 May 2024 | −$0.62 |
| 29 Feb 2024 | −$0.64 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €3.3bn
- Market cap in trading currency
- $3.64bn
- Enterprise value
- $2.69bn
- P/E
- –
- P/S
- –
- P/B
- 3.18
- EV/Sales
- –
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -9.8%
Results (last four quarters)
- Revenue
- $0
- Gross profit
- –
- EBITDA
- −$463m
- Net income
- −$429m
- Earnings per share
- −$4.70
- Revenue per share
- $0.00
- Revenue growth
- –
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity
- -50.3%
- Return on assets
- -35.7%
Balance sheet and cash flow
- Cash
- $951m
- Cash per share
- $9.67
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 21.19
- Book value per share
- $11.66
- Operating cash flow
- −$356m
- Free cash flow
- −$357m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 98.3m
- Volume
- 1.08m
- Avg. volume 3 months
- 1.65m
- Relative volume
- 0.6
Price and technicals
- Price
- $37.04
- 1 day
- −1.4%
- 52-week high
- $70.96
- 52-week low
- $33.49
- Distance to 52-week high
- −47.8%
- Distance to 52-week low
- +10.6%
- Distance to 50-day line
- −5.1%
- Distance to 200-day line
- −29.0%
- RSI (14)
- 41
- Volatility 1M
- 37.4%
Performance
- 1 week
- −8.5%
- 1 month
- +1.5%
- 3 months
- −38.8%
- 6 months
- −31.6%
- YTD
- −17.4%
- 1 year
- −8.9%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has XENE performed since 11/2016?
$10,000 grew to $45,728 by 20 Nov 2026, which is +16.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is XENE?
Volatility was 61.9% per year, measured on monthly returns. The largest decline from a peak was −77.7%, with the low in 11/2017.
How does XENE compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, XENE returned +16.4% at 61.9%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.
Why does this page show a US listing?
The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.